Trimel Pharma's sexual disorder drug effective in mid-stage study
May 28 (Reuters) - Trimel Pharmaceuticals Corp said its experimental sexual disorder drug increased the average number of orgasms in patients with Female Orgasmic Disorder in a mid-stage study.
The company said a 0.6 mg dose of the nasal drug, Tefina, showed a statistically significant increase in the number of orgasms in pre-menopausal and post-menopausal patients with the condition, compared with a placebo.
Female Orgasmic Disorder, also known as anorgasmia, is characterized by a delay, absence or reduced intensity of orgasm, leading to distress. (Reporting by Vrinda Manocha in Bangalore; Editing by Kirti Pandey)
© Thomson Reuters 2017 All rights reserved.